Patent Ductus Arteriosus Stenting in Infants with Duct-Dependent Pulmonary Circulation: An Indian Experience

OBJECTIVE: The study aimed to evaluate outcomes of patent ductus arteriosus (PDA) stenting using the latest generation drug-eluting coronary stents in neonates with duct-dependent pulmonary circulation. METHODS: This was a retrospective, observational study which included infants who were diagnosed with duct-dependent pulmonary circulation and underwent PDA stenting at a tertiary care center in India. All pre- and post-procedural details of each patient were retrospectively collected from the medical records of the hospital. All the patients were regularly followed up for up to 12 months in the outpatient clinic until the subsequent surgical procedure following the PDA-stenting. RESULTS: A total of 58 patients who underwent PDA stenting were included in the study. The mean age was 50.22±67.69 days and mean weight was 3.18±1.15 kg. Among all, 24 (41.4%) patients were prematurely born (<37 gestational weeks). A total of 35 (60.3%) patients required prostaglandins before PDA stenting to maintain patency of the duct until the procedure. The mean PDA diameter at pulmonary artery end was 2.75±0.63 mm, and the mean PDA length was 17.19±4.68 mm. A total of 60 drug-eluting coronary stents were implanted across 58 PDAs with Tetrilimus everolimus-eluting stents being the most implanted (35%). The mean implanted stent length and diameter were 19.50±5.61 mm and 4.06±2.39 mm. Successful stent deployment at the intended position across the PDA was achieved in all 58 (100%) patients. During hospital-stay, four (6.9%) cases of in-hospital mortality were reported. Post discharge, three deaths were reported up to 12-month follow-up. During 12-month follow-up, 19 (32.8%) patients underwent univentricular surgical repair, while four (6.9%) underwent biventricular surgical pair. Two (3.4%) patients required stent retrieval and subsequently underwent palliative shunting. CONCLUSION: The PDA stenting with the latest-generation drug-eluting coronary stents is found safe and clinically better palliative care strategy for patients with duct-dependent pulmonary circulation, resulting in improved procedural and follow-up outcomes.

Authors

Publication Details

Journal
Cardiology
Published
2026-04-30
DOI
https://doi.org/10.1159/000552118
Primary Topic
Cardiovascular Conditions and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Patent Ductus Arteriosus Stenting in Infants with Duct-Dependent Pulmonary Circulation: An Indian Experience

Siddhartha Joshi, Sudipta Bhattacharjya, Somrita Laha, Deepali Bangalia et al.
Cardiology
Cardiovascular Conditions and Treatments
article

Patent Ductus Arteriosus Stenting in Infants with Duct-Dependent Pulmonary Circulation: An Indian Experience

Siddhartha Joshi, Sudipta Bhattacharjya, Somrita Laha, Deepali Bangalia, Santanu Roy, Hemanta Nayak
article en

Abstract

OBJECTIVE: The study aimed to evaluate outcomes of patent ductus arteriosus (PDA) stenting using the latest generation drug-eluting coronary stents in neonates with duct-dependent pulmonary circulation. METHODS: This was a retrospective, observational study which included infants who were diagnosed with duct-dependent pulmonary circulation and underwent PDA stenting at a tertiary care center in India. All pre- and post-procedural details of each patient were retrospectively collected from the medical records of the hospital. All the patients were regularly followed up for up to 12 months in the outpatient clinic until the subsequent surgical procedure following the PDA-stenting. RESULTS: A total of 58 patients who underwent PDA stenting were included in the study. The mean age was 50.22±67.69 days and mean weight was 3.18±1.15 kg. Among all, 24 (41.4%) patients were prematurely born (<37 gestational weeks). A total of 35 (60.3%) patients required prostaglandins before PDA stenting to maintain patency of the duct until the procedure. The mean PDA diameter at pulmonary artery end was 2.75±0.63 mm, and the mean PDA length was 17.19±4.68 mm. A total of 60 drug-eluting coronary stents were implanted across 58 PDAs with Tetrilimus everolimus-eluting stents being the most implanted (35%). The mean implanted stent length and diameter were 19.50±5.61 mm and 4.06±2.39 mm. Successful stent deployment at the intended position across the PDA was achieved in all 58 (100%) patients. During hospital-stay, four (6.9%) cases of in-hospital mortality were reported. Post discharge, three deaths were reported up to 12-month follow-up. During 12-month follow-up, 19 (32.8%) patients underwent univentricular surgical repair, while four (6.9%) underwent biventricular surgical pair. Two (3.4%) patients required stent retrieval and subsequently underwent palliative shunting. CONCLUSION: The PDA stenting with the latest-generation drug-eluting coronary stents is found safe and clinically better palliative care strategy for patients with duct-dependent pulmonary circulation, resulting in improved procedural and follow-up outcomes.

Cardiology
Good health and well-being
Openalex Percentile: Top 9%
Cardiovascular Conditions and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.